CARDIOL THERAPEUTICS CL.A Aktie
WKN: A2PA9E
ISIN: CA14161Y2006
Land: Kanada
Branche: Chemie, Pharma, Bio- & Medizintechnik
Sektor: Biotechnologie
Gratis: Die zehn beliebtesten Rüstungs-Aktien im Check! Info...
0,8665 EUR -0,0245 EUR -2,75 %
09:38:36 L&S RT
Komplette Navigation anzeigen

Mission pro Börse - Börsenwohlstand für Alle! Wann profitieren auch Sie? Info.

EQS-News: Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

Freitag, 16.12.22 18:26
Newsbild
Bildquelle: Fotolia

EQS-News: Cardiol Therapeutics
Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

16.12.2022 / 18:26 CET/CEST
The issuer is solely responsible for the content of this announcement.

0.jpgContact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

[email protected]


News Source: News Direct

16.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: Cardiol Therapeutics
United States
ISIN: CA14161Y2006
EQS News ID: 1515789

 
End of News EQS News Service

1515789  16.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1515789&application_name=news&site_id=boerse_de



Quelle: DGAP



myChampions100PLUS Einzelkontenverwaltung ab 500.000 Euro